959-24-0
959-24-0 結(jié)構(gòu)式
基本信息
鹽酸索他洛爾
BETAPACE
DAROB
MJ-1999
N-[4-[1-HYDROXY-2-[(1-METHYLETHYL)AMINO]ETHYL]PHENYL]METHANESULFONAMIDE HYDROCHLORIDE
N-[4-(1-HYDROXY-2-[ISOPROPYLAMINO]ETHYL)-PHENYL]METHANESULFONAMIDE HYDROCHLORIDE
SOTACOR
SOTALEX
SOTALOL HCL
(+/-)-SOTALOL HYDROCHLORIDE
SOTALOL HYDROCHLORIDE
4-(2-isopropylamino-1-hydroxyaethyl)methanesulfonailidhydrochlorid
4’-(1-hydroxy-2-(isopropylamino)ethyl)methanesulfonanilidemonohydrochloride
4’-(1-hydroxy-2-(isopropylamino)ethyl)-methanesulfonanilidmonohydrochlorid
isopropylaminohydroxyethylmethanesulfonanilidehydrochloride
meadjohnson1999
n-isopropyl-beta-(4-methanesulfonamidophenyl)ethanolaminehydrochloride
SOLATOL HCL
(-N-[4-[1-Hydroxy-2-[(1-Methyl Ethyl) Amino]-ethyl]phenyl]methanesulfonamide
D,L-Sotalol, Hydrochloride
物理化學(xué)性質(zhì)
安全數(shù)據(jù)
959-24-0(安全特性,毒性,儲(chǔ)運(yùn))
常見(jiàn)問(wèn)題列表
1.轉(zhuǎn)復(fù)，預(yù)防室上性心動(dòng)過(guò)速，特別是房室結(jié)折返性心動(dòng)過(guò)速也可用于予激綜合征伴室上性心動(dòng)過(guò)速。
2.心房撲動(dòng)，心房顫動(dòng)。
3.各種室性心律失常，包括室性早搏，持續(xù)性及非持續(xù)性室性心動(dòng)過(guò)速。
4.急性心肌梗死并發(fā)嚴(yán)重心律失常。
| Target | Value |
| β-adrenergic receptor | |
| Potassium channel |
Sotalol hydrochloride (MJ 1999) is an adrenergic β-antagonist that is used in the treatment of life-threatening arrhythmias. Sotalol hydrochloride is a competitive beta adrenoceptor antagonist devoid of membrane-stabilizing activity and intrinsic sympathomimetic activity that has no preferential actions on beta 1 or beta 2 responses. Sotalol hydrochloride causes concentration-dependent increases in the contractility of isolated ventricular tissue that is not blocked by previous beta or alpha blockade or catecholamine depletion. Sotalol hydrochloride consistently reduces the heart rate to a greater degree than propranolol and causes significantly less cardiac suppression than propranolol at a given heart rate.
Sotalol hydrochloride is not only a beta blocker but a class III antiarrhythmic drug. Its possible antifibrillatory activity was therefore investigated in both the ventricles and atria of dog heart in situ, since vulnerability to fibrillation is not the same in both these parts of the myocardium.